Literature DB >> 8741085

Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study.

C Colosimo, M Merello, F E Pontieri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8741085     DOI： 10.1007/bf00869004

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  9 in total

1.  The dopaminergic response in multiple system atrophy.

Authors:  A J Hughes; C Colosimo; B Kleedorfer; S E Daniel; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-11       Impact factor: 10.154

2.  Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.

Authors:  D J Brooks; V Ibanez; G V Sawle; E D Playford; N Quinn; C J Mathias; A J Lees; C D Marsden; R Bannister; R S Frackowiak
Journal:  Ann Neurol       Date:  1992-02       Impact factor: 10.422

Review 3.  The functional anatomy of basal ganglia disorders.

Authors:  R L Albin; A B Young; J B Penney
Journal:  Trends Neurosci       Date:  1989-10       Impact factor: 13.837

4.  Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study.

Authors:  J Kornhuber; J Bormann; M Hübers; K Rusche; P Riederer
Journal:  Eur J Pharmacol       Date:  1991-04-25       Impact factor: 4.432

5.  The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way.

Authors:  J C Stoof; J Booij; B Drukarch; E C Wolters
Journal:  Eur J Pharmacol       Date:  1992-03-31       Impact factor: 4.432

6.  The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice.

Authors:  M Carlsson; A Carlsson
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

7.  Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease.

Authors:  C Colosimo; A Albanese; A J Hughes; V M de Bruin; A J Lees
Journal:  Arch Neurol       Date:  1995-03

Review 8.  Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes.

Authors:  A J Hughes; A J Lees; G M Stern
Journal:  Lancet       Date:  1990-07-07       Impact factor: 79.321

9.  Dopamine: release from the brain in vivo by amantadine.

Authors:  P F Von Voigtlander; K E Moore
Journal:  Science       Date:  1971-10-22       Impact factor: 47.728
  9 in total
  6 in total

Review 1.  Multiple system atrophy: pathophysiology and management.

Authors:  G K Wenning; S Braune
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 2.  The spectrum of differential diagnosis in neurological patients with livedo reticularis and livedo racemosa. A literature review.

Authors:  Markus Kraemer; Dieter Linden; Peter Berlit
Journal:  J Neurol       Date:  2005-08-26       Impact factor: 4.849

3.  Progression of parkinsonism in multiple system atrophy.

Authors:  Klaus Seppi; Farid Yekhlef; Anja Diem; Elisabeth Luginger Wolf; Joerg Mueller; François Tison; Niall P Quinn; Werner Poewe; Gregor K Wenning
Journal:  J Neurol       Date:  2005-01       Impact factor: 4.849

Review 4.  Management of multiple system atrophy: state of the art.

Authors:  C Colosimo; D Tiple; G K Wenning
Journal:  J Neural Transm (Vienna)       Date:  2005-12       Impact factor: 3.575

Review 5.  Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy.

Authors:  Lisa Mészáros; Alana Hoffmann; Jeanette Wihan; Jürgen Winkler
Journal:  Int J Mol Sci       Date:  2020-04-16       Impact factor: 5.923

Review 6.  Four-Repeat Tauopathies: Current Management and Future Treatments.

Authors:  Lawren VandeVrede; Peter A Ljubenkov; Julio C Rojas; Ariane E Welch; Adam L Boxer
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.